Bifogade filer
Kurs
-6,48%
Likviditet
0,22 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-05 | 08:00 | Bokslutskommuniké 2025 |
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-16 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-09 | N/A | X-dag ordinarie utdelning ORX 0.00 SEK |
2025-05-08 | N/A | Årsstämma |
2025-05-06 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-06 | - | Bokslutskommuniké 2024 |
2024-12-18 | - | Extra Bolagsstämma 2025 |
2024-10-24 | - | Kvartalsrapport 2024-Q3 |
2024-07-17 | - | Kvartalsrapport 2024-Q2 |
2024-05-08 | - | Kvartalsrapport 2024-Q1 |
2024-04-29 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2024-04-26 | - | Årsstämma |
2024-02-08 | - | Bokslutskommuniké 2023 |
2023-11-02 | - | Kvartalsrapport 2023-Q3 |
2023-10-26 | - | Extra Bolagsstämma 2023 |
2023-07-18 | - | Kvartalsrapport 2023-Q2 |
2023-04-27 | - | Kvartalsrapport 2023-Q1 |
2023-04-19 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2023-04-18 | - | Årsstämma |
2023-01-26 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-07-14 | - | Kvartalsrapport 2022-Q2 |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-04-22 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2022-04-21 | - | Årsstämma |
2022-01-27 | - | Bokslutskommuniké 2021 |
2021-11-03 | - | Kvartalsrapport 2021-Q3 |
2021-07-15 | - | Kvartalsrapport 2021-Q2 |
2021-04-29 | - | Kvartalsrapport 2021-Q1 |
2021-04-14 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2021-04-13 | - | Årsstämma |
2021-01-28 | - | Bokslutskommuniké 2020 |
2020-11-04 | - | Kvartalsrapport 2020-Q3 |
2020-07-16 | - | Kvartalsrapport 2020-Q2 |
2020-05-19 | - | Extra Bolagsstämma 2020 |
2020-04-28 | - | Kvartalsrapport 2020-Q1 |
2020-04-17 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2020-04-16 | - | Årsstämma |
2020-01-30 | - | Bokslutskommuniké 2019 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-07-11 | - | Kvartalsrapport 2019-Q2 |
2019-05-02 | - | Kvartalsrapport 2019-Q1 |
2019-04-14 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2019-04-11 | - | Årsstämma |
2019-01-30 | - | Bokslutskommuniké 2018 |
2018-10-25 | - | Kvartalsrapport 2018-Q3 |
2018-07-11 | - | Kvartalsrapport 2018-Q2 |
2018-04-26 | - | Kvartalsrapport 2018-Q1 |
2018-04-13 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2018-04-12 | - | Årsstämma |
2018-01-25 | - | Bokslutskommuniké 2017 |
2017-10-19 | - | Kvartalsrapport 2017-Q3 |
2017-07-11 | - | Kvartalsrapport 2017-Q2 |
2017-04-20 | - | Kvartalsrapport 2017-Q1 |
2017-04-07 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2017-04-06 | - | Årsstämma |
2017-01-26 | - | Bokslutskommuniké 2016 |
2016-10-20 | - | Kvartalsrapport 2016-Q3 |
2016-07-12 | - | Kvartalsrapport 2016-Q2 |
2016-04-21 | - | Kvartalsrapport 2016-Q1 |
2016-04-18 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2016-04-15 | - | Årsstämma |
2016-01-28 | - | Bokslutskommuniké 2015 |
2015-10-22 | - | Kvartalsrapport 2015-Q3 |
2015-07-10 | - | Kvartalsrapport 2015-Q2 |
2015-04-23 | - | Kvartalsrapport 2015-Q1 |
2015-04-16 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2015-04-15 | - | Årsstämma |
2015-01-29 | - | Bokslutskommuniké 2014 |
2014-10-22 | - | Analytiker möte 2014 |
2014-10-22 | - | Kvartalsrapport 2014-Q3 |
2014-07-11 | - | Kvartalsrapport 2014-Q2 |
2014-04-25 | - | Kvartalsrapport 2014-Q1 |
2014-04-16 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2014-04-15 | - | Årsstämma |
2014-01-30 | - | Bokslutskommuniké 2013 |
2013-10-23 | - | Kvartalsrapport 2013-Q3 |
2013-08-06 | - | Extra Bolagsstämma 2013 |
2013-07-12 | - | Kvartalsrapport 2013-Q2 |
2013-04-26 | - | Kvartalsrapport 2013-Q1 |
2013-04-12 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2013-04-11 | - | Årsstämma |
2013-03-13 | - | 15-7 2013 |
2013-01-31 | - | Bokslutskommuniké 2012 |
2012-10-25 | - | Kvartalsrapport 2012-Q3 |
2012-09-21 | - | 15-7 2012 |
2012-07-13 | - | Extra Bolagsstämma 2012 |
2012-07-12 | - | Kvartalsrapport 2012-Q2 |
2012-05-03 | - | Kapitalmarknadsdag 2012 |
2012-04-27 | - | Kvartalsrapport 2012-Q1 |
2012-04-12 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2012-04-11 | - | Årsstämma |
2012-01-31 | - | Bokslutskommuniké 2011 |
2011-11-09 | - | Kvartalsrapport 2011-Q3 |
2011-08-10 | - | Kvartalsrapport 2011-Q2 |
2011-05-04 | - | Kvartalsrapport 2011-Q1 |
2011-04-08 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2011-04-07 | - | Årsstämma |
2011-02-16 | - | Extra Bolagsstämma 2011 |
2011-02-16 | - | Bokslutskommuniké 2010 |
2010-11-10 | - | Kvartalsrapport 2010-Q3 |
2010-08-20 | - | Kvartalsrapport 2010-Q2 |
2010-05-05 | - | Kvartalsrapport 2010-Q1 |
2010-04-22 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2010-04-21 | - | Årsstämma |
2010-02-17 | - | Bokslutskommuniké 2009 |
2009-11-10 | - | Kvartalsrapport 2009-Q3 |
2009-08-21 | - | Kvartalsrapport 2009-Q2 |
2009-05-06 | - | Kvartalsrapport 2009-Q1 |
2009-04-24 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2009-04-23 | - | Årsstämma |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Uppsala, Sweden - March 28, 2025 – Orexo’s Annual and Sustainability Report for 2024 has been published. It is attached as a PDF to this press release and can be downloaded at https://orexo.com/investors/.
Nikolaj Sørensen, President and CEO, reflects on 2024: Orexo has made significant strides in overcoming challenges and seizing new opportunities. We achieved EBITDA profitability and resolved key legal and financial uncertainties. Continued stabilization in Zubsolv® demand and the advancement of OX640,[1] along with the ongoing development of the AmorphOX® platform, mean we’re positioned well for a promising 2025. With a dedicated team, we are set to embrace new opportunities to deliver our mission to address critical patient needs and drive shareholder value.”
The Annual and Sustainability Report includes:
- Orexo Overview: Insights covering areas such as operations, markets and investment themes, as well as the CEO's comments and the company’s strategic direction.
- Reports: The Board of Directors Report (incl. the Sustainability Report), the Corporate Governance Report, and Financial Reports and Notes.
The Swedish version is also available on the company´s website in European Single Electronic Format (ESEF).
For more information about Orexo, visit www.orexo.com, and stay updated by following us on X and LinkedIn.
For further information contact: Lena Wange, IR & Communications Director |
Tel: +46 18 780 88 00 |
e-mail: ir@orexo.com |
About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary drug delivery technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees to 110. Orexo is listed on Nasdaq Stockholm’s main list and is available as ADRs on OTCQX market (ORXOY) in the US.
[1] Rescue medication for allergic reactions, incl. anaphylaxis, with powder-based epinephrine.
This information is information that Orexo AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-28 08:00 CET.
Image Attachments
00 Omslag FramsidaXENG V15 26375